Short Interest in Adlai Nortye Ltd. (NASDAQ:ANL) Increases By 89.5%

Adlai Nortye Ltd. (NASDAQ:ANL - Get Free Report) was the recipient of a large growth in short interest during the month of February. As of February 28th, there was short interest totalling 7,200 shares, a growth of 89.5% from the February 13th total of 3,800 shares. Based on an average daily volume of 8,600 shares, the short-interest ratio is currently 0.8 days. Currently, 0.0% of the shares of the stock are sold short.

Adlai Nortye Price Performance

Shares of ANL stock opened at $2.19 on Friday. Adlai Nortye has a 12-month low of $1.85 and a 12-month high of $17.48. The firm has a 50-day moving average price of $2.15 and a 200 day moving average price of $2.25.

Adlai Nortye Company Profile

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.